Seattle Genetics (SGEN) Receives Price Target

Seattle Genetics (SGEN) : The most positive equity analysts on Seattle Genetics (SGEN) expects the shares to touch $130, whereas, the least positive believes that the stock will trade at $38 in the short term. The company is covered by 9 Wall Street Brokerage Firms. The average price target for shares are $57.11 with an expected fluctuation of $28.59 from the mean.

Seattle Genetics (SGEN) : Zacks Investment Research ranks Seattle Genetics (SGEN) as 3, which is a Hold recommendation. 4 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. 1 other analysts are mildly bullish on the stock and favor a Buy. A total of 5 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 10 research analysts is 2.1, which indicates as a Buy.


Also, Cantor Fitzgerald downgrades its view on Seattle Genetics (NASDAQ:SGEN) according to the research report released by the firm to its investors. The shares have now been rated Hold by the stock experts at the ratings house. Earlier, the shares had a rating of Buy. The rating by the firm was issued on July 27, 2016.

Seattle Genetics (NASDAQ:SGEN): During Thursdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $44.72 and $44.13 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $44.97. The buying momentum continued till the end and the stock did not give up its gains. It closed at $44.90, notching a gain of 0.79% for the day. The total traded volume was 440,129 . The stock had closed at $44.55 on the previous day.

Seattle Genetics, Inc. is a biotechnology company focused on the development and commercialization of therapies for the treatment of cancer. The Companys marketed product ADCETRIS, or brentuximab vedotin, is an antibody-drug conjugate (ADC) comprising an anti-CD30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin E (MMAE), utilizing its technology. In addition to ADCETRIS, the Companys pipeline includes six clinical-stage ADC programs consisting of SGN-CD33A, SGN-CD19A, SGN-LIV1A, SGN-CD70A, ASG-22ME, and ASG-15ME, and SEA-CD40, which is based on its sugar-engineered antibody (SEA) technology. In addition, it has multiple preclinical and research-stage programs that employ its technologies. Its technologies include ADC technology and Seattle Genetics sugar-engineered antibody (SEA) technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.